Barclays
FULC icon

Barclays’s Fulcrum Therapeutics FULC Stock Holding History

Barclays’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$247K Sell
66,740
-16,633
-20% -$62.4K ﹤0.01% 3838
2026
Q2 		$305K Sell
83,373
-5,085
-6% -$30.9K ﹤0.01% 3491
2026
Q1 		$678K Sell
88,458
-44,083
-33% -$409K ﹤0.01% 2994
2025
Q4 		$1.5M Buy
132,541
+42,925
+48% +$437K ﹤0.01% 3136
2025
Q3 		$824K Sell
89,616
-22,447
-20% -$162K ﹤0.01% 3487
2025
Q2 		$771K Buy
112,063
+29,606
+36% +$158K ﹤0.01% 3506
2025
Q1 		$237K Sell
82,457
-39,613
-32% -$146K ﹤0.01% 3946
2024
Q4 		$574K Sell
122,070
-2,071
-2% -$7.64K ﹤0.01% 3741
2024
Q3 		$443K Buy
124,141
+97,565
+367% +$724K ﹤0.01% 3856
2024
Q2 		$165K Sell
26,576
-44,939
-63% -$340K ﹤0.01% 3678
2024
Q1 		$675K Buy
71,515
+3,330
+5% +$29.7K ﹤0.01% 3403
2023
Q4 		$460K Buy
+68,185
New +$303K ﹤0.01% 3927
2023
Q3 		– Sell
-144,983
Closed -$478K – 4631
2023
Q2 		$478K Buy
144,983
+117,730
+432% +$346K ﹤0.01% 2778
2023
Q1 		$77.7K Buy
27,253
+15,561
+133% +$139K ﹤0.01% 4300
2022
Q4 		$85.1K Buy
11,692
+10,244
+707% +$66.8K ﹤0.01% 4320
2022
Q3 		$12K Sell
1,448
-265
-15% -$1.9K ﹤0.01% 4231
2022
Q2 		$8K Sell
1,713
-21,667
-93% -$212K ﹤0.01% 4686
2022
Q1 		$553K Buy
+23,380
New +$331K ﹤0.01% 2838

Other funds holding FULC

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Barclays's FULC Position: Q3 2026 in Review

Barclays reduced its Fulcrum Therapeutics (FULC) stake by 20% in Q3 2026, selling an estimated $62.4K and leaving 66,740 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #3838.

Barclays first reported a position in FULC in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.5M in Q4 2025. 42 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

  • Barclays held 66,740 shares of Fulcrum Therapeutics worth $247K as of Q3 2026.
  • Barclays sold 16,633 Fulcrum Therapeutics shares in Q3 2026, an estimated $62.4K.
  • Fulcrum Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3838 holding.
  • Barclays first reported a position in Fulcrum Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Fulcrum Therapeutics position peaked at $1.5M in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.